Coherus Oncology (CHRS) Tax Provisions (2019 - 2023)

Coherus Oncology has disclosed Tax Provisions across 3 years of filings, most recently posting -$380000.0 for Q3 2023.

• In Q3 2023, Tax Provisions changed N/A year-over-year to -$380000.0; the TTM figure through Dec 2023 stood at -$380000.0 (changed N/A YoY), while the FY2025 annual figure was -$38.5 million, up 14.98% from the prior year.
• Tax Provisions came in at -$380000.0 for Q3 2023 at Coherus Oncology, down from $1.1 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $2.0 million in Q4 2019 to a low of -$380000.0 in Q3 2023.
• Average Tax Provisions over 3 years is $760500.0, with a median of $890000.0 recorded in 2019.
• The largest YoY upside for Tax Provisions was 2449.02% in 2020 against a maximum downside of 76.39% in 2020.
• Over 3 years, Tax Provisions stood at $2.0 million in 2019, then slumped by 46.72% to $1.1 million in 2020, then slumped by 134.89% to -$380000.0 in 2023.
• Per Business Quant data, the three most recent Tax Provisions figures were -$380000.0 in Q3 2023, $1.1 million in Q4 2020, and $200000.0 in Q3 2020.